華康生物醫學(08622.HK)預計年度虧損1160萬元
格隆匯 3 月 5日丨華康生物醫學(08622.HK)公佈,預期公司擁有人應占期內虧損截至2020年12月31日止年度約人民幣1160萬元,相比較去年度約人民幣28.4萬元。
董事會預期該年度虧損增加乃主要由於以下相關因素:(i)中國的地區銷售收入倒退約人民幣430萬元,因為自從疫情爆發,中國多個省市已採取緊急公共衞生措施,並採取各種行動預防疫情傳播,包括採取人羣控制或居家政策或命令,而此外疫情亦令集團停止生產及銷售約五個星期;(ii)確認於2020年4月9日授出以股權結算的購股權開支約人民幣270萬元;(iii)確認一次性非現金減值撥備虧損約人民幣260萬元,由集團在對集團的固定資產進行估算和評估並有鑑於疫情對營商和經營環境的不利影響而採納審慎原則後所錄得的記錄;(iv)因外幣兑人民幣匯率波動而出現絕大多數為未實現的匯兑損失約人民幣110萬元,相對去年度匯兑收益約人民幣49.8萬元;和(v)該年度就集團應收賬款確認的減值虧損撥備為約人民幣77.9萬元,相對去年度撥回減值虧損約人民幣25萬元,主要由於疫情影響了集團債務人的償還能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.